NDAOPHTHALMICOINTMENTPriority Review
Approved
Nov 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Priority Review
VIRA-A (vidarabine) by Pfizer. Approved for herpes simplex. First approved in 1976.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIRA-A (vidarabine) is an antiviral ointment approved in 1976 for topical treatment of herpes simplex infections of the eye. It is a nucleoside analog that inhibits viral DNA synthesis. This product represents an older generation antiviral therapy now facing significant competitive pressure from newer agents.
LOE Approaching
As a mature product approaching loss of exclusivity with minimal linked job openings, this represents a legacy brand requiring defensive commercial strategy rather than growth investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Clinical Trials (1)
Comparison of Foscarnet Versus Vidarabine in the Treatment of Herpes Infection in Patients With AIDS Who Have Not Had Success With Acyclovir
26 enrolled
Herpes SimplexHIV Infections
Career Relevance
Zero linked job openings signal minimal active hiring for VIRA-A; positions available are likely defensive maintenance roles focused on market share retention rather than growth. A career move to this product would involve managing decline, supporting existing customer relationships, and potentially planning product transition or discontinuation.
Worked on VIRA-A at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.